Khiron Life Sciences

Discover the evolution of cannabis as Khiron Life Sciences brings its unique medicinal cannabis products to the Latin American, US and global markets.

This profile is part of a paid investor education campaign.*

Overview

A vertically integrated cannabis leader with global growth, Khiron Life Sciences Corp. (TSXV:KHRN) targets a market of 620 million people in Latin America, with operations in Colombia, Uruguay, Chile and a presence in Peru and Mexico, and through a joint venture has entry into the US consumer market.

The Company has cultivation capabilities in multiple jurisdictions and is engaged in the production, distribution, marketing and export of THC and CBD cannabis. Khiron is leading scientific research, clinical trials and education programs, owns and operates a network of medical clinics that treat 100,000 patients annually, and holds endorsements from the foremost medical associations in the region.

Khiron’s Kuida® cosmeceutical brand, the first mass-market branded CBD skincare line in the LatAm region is distributed at retail and online across Colombia, and with secure entry to Mexico, Peru and the United States forms the basis of the Company’s wellness unit.

The Company has a highly experienced management team, and influential board representation including the 55th president of Mexico and former CEO of Coca Cola Mexico, Vicente Fox, and global retail brand entrepreneur Joseph Mimran who sits on the board of the Company’s Colombia subsidiary.

With corporate offices in Bogota, Colombia and over 200 employees, Khiron lists on the TSXV exchange (“KHRN”), Frankfurt (“A2JMZC”) and the OTCQB market (“KHRNF”).

Company Highlights

  • Operations in 3 countries in Latin America (Colombia, Chile and Uruguay).
  • Licensed for 2.4 Million sqft. of capacity for 220,000 kg of dry flower production, with 5,640,000 sq.ft. of total capacity in all licensed countries
  • Khiron’s capacity to export both, THC and CBD extracts (medicinal from Colombia) and dry flower (from Uruguay), allows Khiron to leverage low-cost cultivation to tackle the $140 billion European market.
  • Distribution channels of branded products:
    • Medical products distribution through wholly-owned clinics
    • Wellness LatAm and US retail distribution
  • Started commercial sales in Colombia in 2018, with products approved in other LatAm countries.
  • Educational and R&D approach to drive patient prescriptions into revenues, through six LatAm patient association endorsements and clinical trials execution for 2019.

Multibillion-Dollar Market Opportunity in Latin America

Expected to be worth over $12 billion USD by 2028 according to consultancy Prohibition Partners, the Latin American market for cannabis is one of the fastest growing markets in the world. Regulatory change is rapidly rippling across the region; 11 countries, including Colombia, Chile and Uruguay have legalized medical cannabis, and three further have decriminalized the use of personal amounts. With a total population of 620 million people and a potential cannabis patient pool of 68 million, the region is quickly emerging as the next stage for leading cannabis companies and investors to deploy capital and expand operations.

With operations in Colombia, a presence in Mexico, Uruguay, Chile and Peru, and access to Brazil through the Mercosur Regional Free Trade Bloc, Khiron Life Sciences is a leading, established player providing investor exposure to the Latin American market. Most recently, the company has announced plans to enter the US consumer market through a joint venture agreement with Dixie Brands. Collectively, these markets represent more than 75% of the total Latin American population of 620 million people, plus almost 60 million Hispanic US citizens that represent the company’s initial focus in that market.

Latin American Market of 620 Million People and 68 Million Potential Patients

Khiron’s Vertically Integrated Advantage

Khiron’s business model is tied intrinsically with developing valuable products for a loyal patient base.  From cultivation and processing, to branded products, to distribution, the company has developed a comprehensive market entry strategy which focuses primarily on fully understanding market needs and regulatory environments before actively engaging doctors and patients.

Cultivation and Processing

As a vertically-integrated company, Khiron cultivates its own cannabis plants, which are then processed for the production of its branded medical, compassionate use, wellness and adult use products. Leveraging Latin America’s ideal climate, low-cost labor, and agricultural know-how, the company’s cultivation and processing operations are optimized for abundant, pharmaceutical-grade growth.

In its cultivation process, the company employs a hydroponic method, which eliminates the use of heavy metals and pesticides, and incorporates state-of-the-art technology designed for all climatic requirements. A recirculation system provides the plants with all their needs according to their growth stage, while a temperature and humidity control system ensures that the plant grows in a controlled natural environment. Using detectors that monitor the amount of CO2, the relative humidity and the temperature inside the greenhouse are under permanent control. This ensures a clean, healthy and high safety standard that allows the generation of high-quality pharmaceutical product.

To ensure consistency in each product, Khiron utilizes a gas extraction method; this process eliminates the presence of alcohols and allows exact amounts of THC and CBD to be obtained. This precision in extraction facilitates the developments of products which are precisely tailored to the medical condition to be treated.

Branded Products

Khiron’s core phytotherapeutics unit is focused on the development of branded medicinal cannabis products that will improve the quality of life for 68 million patients across the Latin America region (Source: QuintileIMS). Its medical and compassionate use products aim to deliver the benefits of cannabis consistently, innovatively and affordably, and are targeted to address the main symptoms associated with common ailments including depression, anxiety, epilepsy and chronic pain.

The company is currently developing a variety of specific formulations of THC and CBD compounds for patients that will be available both over the counter and by prescription. It has a portfolio of more than 25 varieties that are currently under Colombian conditions evaluation in order to build a full agronomic and chemical profile of each variety and gain information to treat different medical conditions.

The company’s products are produced utilising standard operating procedures for medicinal cannabis, medical-grade varieties and GMP-compliant methods of extraction and product formulation.

In the domestic market of Colombia and Latin America, Khiron will primarily distribute its products through a regional network of physicians that is being built in co-ordination with the region’s most respected medical associations.

As part of its branded product portfolio, Khiron has also established a wellness business unit focused on cosmeceutical and nutraceutical products which offer the full benefits of cannabis to consumers across Latin America. The wellness unit was introduced with the launch of its initial consumer brand Kuida, the first mass-market CBD brand in Colombia that brings the benefits of cannabidiol to a comprehensive portfolio of skin and body care products for women. Since its introduction, Kuida has been distributed across Colombia through retail, wholesale and online channels.

Distribution

In the domestic market of Colombia and Latin America, Khiron will primarily distribute its products through a regional network of physicians that is being built in co-ordination with the region’s most respected medical associations.

For this reason, the company has established the Khiron Clinics Unit with the aim of giving patients alternative treatments, from existing medicines to the safer and more effective alternative of cannabinoids and building a robust network of affiliated clinics and doctors across Latin America. One of the cornerstones of the Khiron clinics business unit is the Latin American Institute of Neurology and the Nervous System. ILANS is one of the most respected and largest health service network providers in Colombia. With two well established and large neurological clinics located in Bogota and 60 licensed physicians and clinicians, the ILANS network serviced an estimated 100,000 patients throughout 2018. Further, Khiron has initiated the rollout of its own branded clinics, known as Zerenia, which help to establish a strong retail presence in major metropolitan areas of Colombia to educate and inform patients on medicinal cannabis

Khiron has also established a medical education programme across Colombia, Mexico and Chile, with plans for future expansion across Latin America. The education programme includes Khiron-hosted and sponsored events and conferences, which are organised in partnership with leading medical associations, including the Colombian Association of Neurology, Colombian Association of Internal Medicine, Colombian Association of Palliative Care, Colombian Association for the Study of Pain, Mexican College of Internal Medicine and Mexican Academy of Neurology, in order to educate physicians about medicinal cannabis. Events are education based, with global research and insight on medicinal cannabis and information platforms to support doctors and healthcare professionals in providing medicinal cannabis treatment options.

Khiron’s Strategy at Work Across the Americas

Colombia

In Colombia, where Khiron is based, the company operates a 1,900,000-square-foot site in Ibague. With a total cultivation capacity of 100,000kg per year, these facilities include a Phase 1A state-of-the-art 80,000-square-foot greenhouse. Located in a highly secure region of Colombia, the cultivation site has an ideal climate profile, abundance of water, power and skilled labour to scale cultivation. In its production and cultivation processes, the company has further developed and follows an extremely stringent legal framework that includes being the first medicinal cannabis producer in Colombia to implement US Drug Enforcement Agency (DEA) level security protocols. Khiron is fully licensed by Colombian authorities to cultivate, produce, distribute domestically and export internationally both tetrahydrocannabinol and cannabidiol medicinal cannabis.

In Colombia, the company has further begun educating and interacting with local institutions and medical associations, while also engaging key opinion leaders in the space. These programs are aimed at reaching the country’s estimated market of six million potential patients.

Uruguay and Brazil

Through its acquisition of NettaGrowth International Inc. (subject to TSX approval), Khiron is also present in Uruguay, its third cultivation jurisdiction in Latin America. NettaGro owns Dormul, which has obtained the first licence to produce medicinal cannabis with THC for commercialisation in Uruguay. Through Dormul, Khiron will be licensed to grow up to 120,000kg of medicinal cannabis in an initial 540,000- square-foot area located in Juan Lacaze.

Its agreement with NettaGro in Uruguay also allows the company access to an export market of Southern Brazil through the Mercosur Regional Free Trade Bloc. Production in Uruguay will concentrate on servicing the medical needs of the 75 million population in the Southern Brazilian region.

Chile

With 1.8 million potential patients (Source: Quintiles IMS), Chile has an established medicinal cannabis culture and was the first country in Latin America to adopt legislation to allow the cultivation of cannabis for medical purposes. Subject to TSX approval, Khiron has also entered the Chilean market through a partnership with Fundación Daya, the first medicinal cannabis permit holder in Chile.

Through this collaboration, Khiron has entered the market with DayaCann’s available cultivation capacity to participate in clinical trials and to develop and distribute medicinal cannabis products across Chile. Under the agreement, Khiron and Fundación Daya have agreed to cultivate up to 1000kg of dried flower to be used to formulate two products targeting patients with neuropathic pain and epilepsy.

Peru

Peru is the sixth country in Latin America to create a legalised medicinal cannabis environment with laws that allow for the production, import and commercial sale of cannabis for medical use. The company has received approval to commercialise four key products in the company’s Kuida CBD cosmeceutical product line in Peru. This approval by Peru’s executive director of the Directorate of Medical Devices and Health Products of the General Directorate of Medications, Supplies and Drugs (DIGEMID) brings Kuida products to a population of 32 million people in Peru.

Mexico

In Mexico, Khiron is well positioned to reach the market of 11.7 million potential patients for medicinal cannabis (Source: Quintile IMS). The company is working closely with Centro Fox, a think tank founded by Fox that concentrates its efforts on creating a new understanding about medicinal cannabis within the patient and medical community in Mexico. In April 2019, Khiron Life Sciences and Centro Fox will co-host the CannaMexico World Summit, an international summit focused on showing the potential of the cannabis industry in Mexico. The conference will bring together leaders from the public, scientific and business sectors for an in-depth exploration of legal regulations, market opportunities, medical advances, innovation and wellness.

United States

As part of a joint venture agreement with Dixie Brands Inc. (subject to TSX approval), Khiron Life Sciences is also positioned to enter the US market for consumer cannabis products. Under the agreement, Dixie will also manufacture and distribute Khiron’s Kuida brand of CBD-based cosmeceuticals in the multibillion-dollar US cosmetic market. Kuida will be one of the first CBD brands targeting the US Hispanic population, estimated at almost 60 million.

Management Team

Alvaro Torres—CEO & Director

Mr. Torres has over 15 years of experience in the Latin American market, including infrastructure projects and project finance, management strategy, team development, and mergers and acquisitions. Prior to co-founding Khiron Life Sciences, Mr. Torres was previously head of business development for SNC-Lavalin, Colombia, and was instrumental in growing the company from two people to more than 2,000 people in Colombia over the course of three years. Alvaro has overseen the development of projects totaling over $1 billion in capital expenditure, including the development and construction of Colombia’s tallest skyscraper. Mr. Torres holds a Bachelor of Engineering and a Masters of Engineering from Rensselaer Polytechnic Institute and an MBA from Georgetown University.

Andres Galofre—VP Business Development

As co-founder of Khiron Life Sciences, Andrés Galofre brings 15 years of experience in pharmaceutical marketing, brand management and distribution of prescription drugs and consumer products in Latin America. Mr. Galofre was integral in leading the launch of Advil in the Colombian market, which reached a 28% domestic market share. In the last five years, Mr. Galofre has been Marketing Manager for Alpina, Founder of VeggiesBox and VP of Business Development of Khiron Life Sciences Corp. Mr. Galofre has a Bachelor of Business Administration from CESA and an MBA from La Trobe University.

Chris Naprawa—President

Mr. Naprawa brings extensive institutional capital markets experience to the Company. Prior to joining Khiron, Mr. Naprawa was Partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities, and Managing Director at Primary Capital. He was also previously founder and CEO of Startcast Solutions, a company successfully sold to a large telecommunications company. Mr. Naprawa holds a Bachelor of Arts from Queen’s University.

Darren Collins—CFO

Mr. Collins is a financial professional focused on the financial development of growth companies globally. He has been involved in over a billion dollars of transactions, and his expertise spans mergers and acquisitions, debt and equity financings, go-public transactions, commercial partnerships, capital budgeting and financial accounting. Prior to his current activities, Mr. Collins was engaged by investment and merchant banks, including Alegro Capital, LP in London, England, and Scotia Capital Inc. and Quest Capital Corp. (currently Sprott Resource Lending Corp.) in Toronto, Canada. In addition, he was previously Chief Financial Officer of an e-commerce company focused on the global distribution of vaporizers and accessories. Mr. Collins holds a Bachelor of Commerce degree in finance from Dalhousie University.

Juan Diego Alvarez—VP Regulatory

Mr. Alvarez has 10 years of legal experience in Colombia and is an authority on Colombian medicinal cannabis regulation. He was previously a public policy advisor to the Ministry of Health in Colombia. In the last five years, Mr. Alvarez has been a consultant for Payson Center for International Development and USAID, a Professor of Law at the University of Los Andes, and VP Regulatory of Khiron Life Sciences Corp. Mr. Alvarez holds an LL.B from the University of Los Andes, a JD from Tulane University, an LL.M from Columbia University and is a PhD law candidate.

Matt Murphy—VP Compliance

Mr. Murphy is an executive leader with broad based domestic and international expertise in both the federal and private sectors. As a Career Special Agent (25 years) with the DEA, he served in a multitude of positions prior to founding the Pharma Compliance Group (PCG). Mr. Murphy is an internationally recognized security expert in the fields of drug law enforcement, risk assessment and system development, regulatory compliance, and training. Mr. Murphy will support the Company by implementing closed loop systems to prevent product diversion and to enhance protocols across Khiron’s plant to patient value chain.

Juan Carlos Álvarez—VP Pharma – Medical

Mr. Álvarez has over 27 years of experience leading in the pharmaceutical industry and directing marketing and sales areas for medicine lines. Experience in supply chain, distribution channels, new product launching and market opening for laboratories like Genfar, Procaps and Siegfried. He studied business management and he holds a MBA from Université du Quebec a Chicoutimi.

Jairo Espinoza—VP Medical Affairs

Dr. Jairo Espinoza has over 16 years of medical experience, specializing in stereotactic and functional neurosurgery to help with the control of chronic pain faced by his patients. He is noted for founding the Latin American Institute of Neurology and Nervous System (ILANS) in Colombia which is a network of neurological institutions, providing interdisciplinary diagnosis and treatment of diseases in the nervous system. He is actively involved in the medical community, having served on the Board of Directors for the World Society for Functional and Stereotactic Neurosurgery from 2010 to 2018 and as the President of the Sociedad Latinoamericana de Neurocirugía Funcional y Estereotáctica (SLANFE) from 2010 to 2012.

Maria-Fernanda Arboleda—Medical Director

Dr. Maria Fernanda Arboleda is an Anesthesiologist, Pain and Palliative Care Physician. She also completed a Spine-Regional Anesthesia Fellowship at the McGill University Health Center and most recently, she completed a Post-Doctoral Research Fellow in Supportive Cancer Care and Medical Cannabis, at the Department of Oncology, McGill University, and at Santé Cannabis, a leading specialized cannabis clinic in Canada. Presently, Dr. Arboleda is the Medical Director of Khiron Life Sciences Corp. Likewise, she is a co-investigator on several research projects that are being developed in Canada, including the deployment of a phase II study on the use of cannabis oil capsules for chronic pain, as well as the first phase III study for the use of inhaled cannabis to improve health-related quality of life in advanced cancer patients.

Edwin Bendek—Skin Unit Medical Director

Dr. Bendek is a dermatologist with over 20 years of experience in cutaneous surgery, anti-aging dermatology, regenerative medicine and predictive genetics. He has a master’s degree in public health from the Universidad de Granada, Spain and in bioethics, health and law from the Université de Rennes in France. He’s a member of the Ethics and Investigations Committee of the Colombian Association of Dermatology. Dr. Bendek is a pioneer in CBD cosmeceutical product innovation.

Ryan Douglas—Master Grower

Ryan has over 15 years of experience growing up to 600,000 plants annually in large commercial greenhouses across north America. He was the Master Grower of Tweed, managing the operations of a 40,000 ft facility.

Marco Algorta—Director at CannaPur

Marco has been in the cannabis industry since 2013.Working closely with the University of the Republic, Marco promotes the advancement of medicinal scientific investigation projects. He is a Co-Founder of the Associação CANNAB in Brazil for research and development of medicinal cannabis and works with the SmartHemp accelerator for industry-related start-ups.


 

*Disclaimer: This profile is sponsored by Khiron Life Sciences Corp. (TSXV:KHRN). This profile provides information which was sourced by the Investing News Network (INN) and approved by Khiron Life Sciences Corp., in order to help investors learn more about the company. Khiron Life Sciences Corp. is a client of INN. The company’s campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Khiron Life Sciences Corp. and seek advice from a qualified investment advisor.